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Abstract
Objective:  The  use  of  probiotics  is  increasingly  popular  in  preterm  neonates,  as  they  may  pre-
vent necrotizing  enterocolitis  sepsis  and  improve  growth  and  feeding  tolerance.  There  is  only
limited literature  on  Saccharomyces  boulardii  CNCM  I-745  (S.  boulardii)  in  preterm  infants.
Method: A  prospective,  randomized,  case-controlled  trial  with  the  probiotic  S.  boulardii
(50 mg/kg  twice  daily)  was  conducted  in  newborns  with  a  gestational  age  of  30--37  weeks  and
a birth  weight  between  1500  and  2500  g.
Results:  125  neonates  were  enrolled;  63  in  the  treatment  and  62  in  the  control  group.  Weight
gain (16.14  ±  1.96  vs.  10.73  ±  1.77  g/kg/day,  p  <  0.05)  and  formula  intake  at  maximal  enteral
feeding (128.4  ±  6.7  vs.  112.3  ±  7.2  mL/kg/day,  p  <  0.05)  were  signiﬁcantly  higher  in  the  inter-
vention group.  Once  enteral  feeding  was  started,  the  time  needed  to  reach  full  enteral  feeding
was signiﬁcantly  shorter  in  the  probiotic  group  (0.4  ±  0.1  vs.  1.7  ±  0.5  days,  p  <  0.05).  There  was
no signiﬁcant  difference  in  sepsis.  Necrotizing  enterocolitis  did  not  occur.  No  adverse  effects
related to  S.  boulardii  were  observed.
Conclusion:  Prophylactic  supplementation  of  S.  boulardii  at  a  dose  of  50  mg/kg  twice  a  day
improved  weight  gain,  improved  feeding  tolerance,  and  had  no  adverse  effects  in  preterm
infants >30  weeks  old.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
 Please cite this article as: Xu L, Wang Y, Wang Y, Fu J, Sun M, Mao Z, et al. A double-blinded randomized trial on growth and feeding
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∗ Corresponding author.
E-mail: maozq@sj-hospital.org (Z. Mao).
ttp://dx.doi.org/10.1016/j.jped.2015.08.013
021-7557/© 2016 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S.  boulardii  in  preterm  infants  297
PALAVRAS-CHAVE
(In)Tolerância  de
alimentac¸ão;
Crescimento;
Enterocolite
necrosante;
Neonato  prematuro;
Probiótico;
Sepse
Ensaio  duplo-cego  randomizado  sobre  crescimento  e  tolerância  de  alimentac¸ão  com  a
Saccharomyces  boulardii  CNCM  I-745  em  neonatos  prematuros  alimentados
com  fórmula
Resumo
Objetivo:  O  uso  de  probióticos  está  cada  vez  mais  popular  em  neonatos  prematuros,  já  que
podem prevenir  a  enterocolite  necrosante  (ECN)  e  a  sepse  e  aumentar  o  crescimento  e  a  tol-
erância de  alimentac¸ão.  Há  apenas  uma  literatura  limitada  sobre  a  Saccharomyces  boulardii
CNCM I-745  (S.  boulardii)  em  neonatos  prematuros.
Método:  Um  ensaio  de  caso-controle  prospectivo  randomizado  com  o  probiótico  S.  boulardii
(50 mg/kg  duas  vezes  por  dia)  foi  realizado  com  recém-nascidos  com  idade  gestacional  de  30  a
37 semanas  e  peso  ao  nascer  entre  1500  e  2500  g.
Resultados:  Foram  incluídos  125  neonatos,  63  no  grupo  de  tratamento  e  62  no  de  controle.  O
ganho de  peso  (16,14  ±  1,96  em  comparac¸ão  a  10,73  ±  1,77  g/kg/dia,  p  <  0,05)  e  a  ingestão  de
fórmula com  nutric¸ão  enteral  máxima  (128,4  ±  6,7  em  comparac¸ão  a  112,3  ±  7,2  mL/kg/dia,
p <  0,05)  foram  signiﬁcativamente  maiores  no  grupo  de  intervenc¸ão.  Assim  que  a  nutric¸ão
enteral foi  iniciada,  o  tempo  necessário  para  atingir  a  nutric¸ão  enteral  completa  foi  signiﬁca-
tivamente menor  no  grupo  probiótico  (0,4  ±  0,1  em  comparac¸ão  a  1,7  ±  0,5  dia,  p  <  0,05).  Não
houve nenhuma  diferenc¸a  signiﬁcativa  em  sepse.  Não  ocorreu  ECN.  Não  foi  observado  nenhum
efeito colateral  relacionado  à  S.  boulardii.
Conclusão:  A  suplementac¸ão  proﬁlática  de  S.  boulardii  a  uma  dose  de  50  mg/kg  duas  vezes  por
dia melhorou  o  ganho  de  peso,  aumentou  a  tolerância  de  alimentac¸ão  e  não  teve  nenhum  efeito
colateral em  neonatos  prematuros  >30  semanas  de  idade.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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IIntroduction
The  gastrointestinal  (GI)  barrier  function,  gut  motility,
mucosal  immunity,  and  digestive/absorptive  capacity  are
all  signiﬁcantly  underdeveloped  in  the  preterm  neonate.1
Preterm  infants  have  an  increased  risk  of  poor  growth,
nosocomial  infections,  and  necrotizing  enterocolitis  (NEC),
and  of  developing  a  different  intestinal  microbiota  than
healthy  breast  fed  infants.1,2 The  latter  is  related  to  a
higher  incidence  of  delivery  through  cesarean  section,
decreased  exposure  to  maternal  microbiota,  increased
exposure  to  organisms  that  colonize  neonatal  intensive  care
units  (NICUs),  antibiotics  (multiple  courses),  and  delay  in
enteral  feeding.3
The  role  for  probiotics  in  the  care  of  preterm  newborns
is  debated.  Probiotics  are  deﬁned  as  ‘‘live  microorganisms
which,  when  administered  in  adequate  amounts,  confer  a
health  beneﬁt  to  the  host’’.4 While  reports  of  improved
growth  and  a  decreased  incidence  of  NEC  are  enticing,  many
aspects  on  the  mechanisms  of  action  are  still  unclear.5,6
Studies  have  used  different  strains  and  dosages,  making  it
difﬁcult  to  draw  evidence-based  conclusions.5--7
Until  now,  researchers  often  selected  strains  belonging
to  bacterial  species  naturally  present  in  the  intestinal  ﬂora,
such  as  lactobacilli  and  biﬁdobacteria.8 Saccharomyces
boulardii  CNCM  I-745  (S.  boulardii)  is  a  probiotic  yeast
isolated  from  the  peel  of  fruits  such  as  lychees,  grow-
ing  in  Indochina.9 S.  boulardii  has  been  poorly  studied  in
preterm  and  low  birth  weight  infants.  The  objective  of  the
present  study  was  to  asses  if  S.  boulardii  administered  to
w
b
sormula-fed  preterm  newborns  >30  weeks  of  gestational  age
ould  improve  weight  gain  and  clinical  outcome.
ethods
atient  inclusion
table  formula  fed  preterm  neonates  admitted  to  the  NICU
f  the  Shengjing  Hospital  of  the  China  Medical  University
n  Shenyang  (China)  were  included  in  this  prospective  ran-
omized  controlled  double-blinded  study,  performed  from
pril  to  July  2013.  Informed  consent  was  obtained  from
he  infants’  parents/guardians.  The  study  protocol  was
pproved  by  the  University  Hospital  Ethical  Committee.
The  sample  size  was  calculated  prior  to  the  start  of  the
tudy  for  a  signiﬁcance  level  of  p  <  0.05  (two-sided),  with  a
ower  of  80%  (ˇ  =  0.2)  to  estimate  the  needed  sample  size,
nd  with  a  weight  gain  standard  deviation  of  9  g/day  in  both
roups  and  a  weight  gain  difference  between  the  two  groups
f  5  g/day.  This  resulted  in  a  sample  size  of  125  infants,
onsidering  a  20%  drop  out  rate.
nclusion  and  exclusion  criteria
nclusion  criteria  were  hospital-born  formula-fed  infants
ith  a  gestational  age  of  30--37  weeks  and  a  birth  weight
etween  1500  and  2500  g.
Exclusion  criteria  were  severe  neonatal  pathologies,
uch  as  severe  birth  complications,  GI  malformations,
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vs.  112.3  ±  7.2  mL/kg/day,  p  <  0.05)  was  higher  in  the  S.
boulardii  than  in  the  control  group,  and  the  time  needed
to  reach  full  enteral  feeding  (0.4  ±  0.1  vs.  1.7  ±  0.5  day,
Random ized 
S. Boulardii group 
Control group : no  prob iotics 
Drop  out  Drop  out  
Premature and  low birth  weigh t 
infants who me t includ ing cr iteria 
n=12598  
hromosomal  abnormalities,  known  immunodeﬁciency,
ydrops  fetalis,  central  venous  catheter,  antifungal  drugs,
nd  probiotics.  All  included  patients  received  parenteral
utrition  and/or  preterm  formula.  No  neonates  received
other’s  milk.  Minimal  enteral  nutrition  or  trophic  feeding
as  started  as  soon  as  possible  at  1  mL/kg/day.  Minimal
nteral  feeding  is  the  practice  of  feeding  small  volumes
f  enteral  feed  in  order  to  stimulate  the  development  of
he  immature  GI  tract  of  the  preterm  infant;  it  improves
I  enzyme  activity,  hormone  release,  blood  ﬂow,  motility,
nd  microbial  ﬂora.  Clinical  beneﬁts  include  improved  milk
olerance,  greater  postnatal  growth,  reduced  systemic
epsis,  and  shorter  hospital  stay.10 As  soon  as  minimal
nteral  feeding  was  tolerated,  the  patient  was  randomly
llocated  to  one  of  two  groups  at  a  1/1  ratio  (S.  boulardii
r  control  group).  Randomization  was  conducted  according
o  a  random  computer-determined  allocation  order  consid-
ring  birth  weight.  Feeding  volume  was  increased  when  it
as  well  tolerated  according  to  the  local  protocol.
ntervention
he  intervention  group  received  S.  boulardii  CNCM  I-745,
dministered  two  times  per  day  as  separate  medication,
ot  mixed  with  formula,  at  a  dosage  of  50  mg/kg  (Bioﬂor®;
MS  Shenzhen  Kangzhe  Pharmaceutical  Co.  Ltd.,  Shen-
hen,  China;  manufactured  by  Biocodex,  Paris,  France);
0  mg  is  approximately  109 colony  forming  units  (CFU).  The
osage  of  the  probiotic  was  derived  from  previous  stud-
es  in  neonates.11 Nothing  was  administered  to  the  control
roup.  The  study  period  ended  at  the  28th  day  after  birth
r  when  the  infant  was  discharged  from  the  hospital,  if  this
as  possible  earlier.  However,  the  minimal  duration  of  the
ntervention  was  at  least  7  days.  Observational  and  rou-
ine  clinical  data  were  collected  from  all  infants.  Blinding
as  possible  because  the  nursing  staff  who  administered  S.
oulardii  to  the  infants  was  not  involved  in  the  daily  care
nd  the  attending  neonatal  team  was  unaware  of  the  ran-
omization  assignments.
utcome
rimary  outcomes  were  short-term  growth  parameters:
eight  gain  (g/kg/day)  and  linear  growth  (cm/week).  Sec-
ndary  outcomes  included:  days  of  parenteral  nutrition
eeded  to  reach  full  enteral  feeding,  maximal  enteral
eeding  volume  tolerated  (mL/kg/day),  and  duration  of  hos-
italization  (days).  Feeding  intolerance  was  deﬁned  when
omiting  and  gastric  residuals  were  considered  too  impor-
ant.  Complications  were  deﬁned  as  incidence  of  NEC
deﬁned  as  suspected  or  conﬁrmed  positive  Bell  stage  II  or
ore)  and  sepsis  (deﬁned  as  positive  blood  culture).9
tatistics-registration
he  data  were  collected  and  entered  into  a  statistical
atabase  (SPSS,  version  16.0;  IBM,  Armonk,  USA).  The  data
re  presented  as  mean  ±  standard  deviation.  The  demo-
raphic  data  and  procedure  variables  were  analyzed  using
he  t-test  or  the  chi-squared  test.  A  p-value  of  <0.05  wasXu  L  et  al.
onsidered  to  indicate  a  statistically  signiﬁcant  difference.
his  study  did  not  receive  external  funds,  and  was  registered
t  the  website  https://clinicaltrials.gov  under  the  number
CT02310425.
esults
atient  description
 total  of  125  formula-fed  preterm  neonates  were  enrolled
nd  randomly  allocated.  Sixty-three  patients  received  S.
oulardii  as  soon  as  they  could  tolerate  minimal  enteral
eeding  and  62  neonates  were  included  in  the  control  group.
n  total,  25  (20%)  patients  were  considered  dropouts  (12
19.1%]  in  the  S.  boulardii  group  and  13  [20.1%]  in  the  con-
rol  group)  (Fig.  1).  Reasons  for  dropout  were  withdrawal
f  consent  (n  =  9),  loss  to  follow-up  (n  =  11),  central  venous
atheter  (n  =  1),  congenital  syphilis  (n  =  1),  and  inappropri-
te  inclusions  (congenital  intestinal  atresia  [n  =  2],  trisomy
1  [n  =  1]).  Fifty-one  subjects  could  be  analyzed  in  the
ntervention  group  and  49  in  the  control  group.  The  charac-
eristics  of  all  neonates  at  study  entry  are  listed  in  Table  1,
nd  did  not  show  any  statistically  signiﬁcant  difference.
S.  boulardii  was  administered  for  the  ﬁrst  time  at  2.63
ays  after  birth  (range:  day  1  to  day  6;  in  46  infants  within
 days,  and  in  only  ﬁve  infants  between  day  4  and  6).  The
otal  number  of  days  of  S.  boulardii  administration  averaged
5.3  days  (range:  9--28  days).
eeding  tolerance
ormula  intake  at  maximal  enteral  feeding  (128.4  ±  6.7Allocated to
S. bou lardii  group
 
Allocated to 
control group
Figure  1  Study  ﬂow  chart.
S.  boulardii  in  preterm  infants  
Table  1  Characteristics  (mean  +  1  SD)  of  the  included
infants.
S.  boulardii  Control
Birthweight  (g)  1947  ±  54  1957  ±  51
Gestation  age  (weeks)  33  +  0.72  33  +  1.04
Boys/girls  27/24  24/25
Respiratory  difﬁculties  5  6
Hyperbilirubinema  (n  [%])  16  (31.4%)  14  (28%)
Maximal  total  bilirubin
(mol/L)
18.5  ±  2.2  19.4  ±  2.8
Anemia  (n  [%]) 23  (45.1%) 25  (51.0%)
Antibiotic  treatment  (n  [%]) 11  (21.6%) 9  (18.4%)
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1Respiratory difﬁculties: includes respiratory distress syndrome
and wet lung.
S, Saccharomyces;  p > 0.05 (all).
p  <  0.05)  was  shorter  in  the  intervention  than  in  the  control
group  (Table  2).
Growth  and  hospital  stay
The  weight  gain  in  the  S.  boulardii  group  was
16.14  ±  1.96  g/kg/day  versus  10.73  ±  1.77  g/kg/day
(p  <  0.05)  in  the  control  group.  There  was  no  signiﬁ-
cant  difference  in  linear  growth,  head  circumference
growth,  incidence  of  abdominal  distension,  and  incidence
of  sepsis  (Table  2).  Hospital  stay  in  the  S.  boulardii  group
was  shorter  (p  =  0.035)  (Table  2).  No  infants  developed  NEC.
Adverse  effects
No  preterms  developed  fungemia,  and  no  adverse  reactions
to  S.  boulardii  were  reported.
Discussion
This  study  demonstrated  that  S.  boulardii  can  safely  be
administered  to  preterm  infants,  and  that  it  improves  oral
feeding  tolerance  and  weight  gain.  In  term  infants,  for-
mula  supplemented  with  Lactobacillus  (L.)  rhamnosus  GG
was  shown  to  increase  weight  gain,  but  formulas  sup-
plemented  with  Biﬁdobacterium  (B.)  longum,  B.  animalis
c
t
r
n
Table  2  Comparison  of  weight  gain,  growth  (mean  +  1  SD),  feedi
toms), and  duration  of  hospitalization  between  the  S.  boulardii  an
S.  bo
Weight  gain  (g/day)  16.14
Max enteral  feeding  (mL/kg/day)  128.4
From start  of  feeding,  time  needed  until  full
enteral  feeding  (days)
0.37  
HC increase  (cm/week)  0.74  
Linear growth  (cm/week) 0.89  
Incidence of  sepsis  (n  [%])  4  (7.
Incidence GI  symptoms  (n  [%]) 7/51
Hospital stay  (days)  23.3  
HC, head circumference; GI, gastrointestinal symptoms: regurgitation,299
ubsp.  lactis, and  L.  reuteri  did  not.11--13 In  preterm  infants,
dministration  of  B.  breve  also  improved  weight  gain.14 The
echanisms  by  which  weight  gain  is  affected  are  not  yet
lear.
S.  boulardii  is  effective  in  the  treatment  of  a  number  of
I  disorders  related  to  the  presence  of  bacterial  and  viral
athogens.15 It  competes  with  pathogens  for  binding  sites
nd  produces  a wide  range  of  antimicrobial  substances.16
.  boulardii  has  the  ability  to  produce  polyamines,  which
re  substances  essential  for  cell  growth  and  differentia-
ion  and  enhance  intestinal  maturation,  what  is  reﬂected
n  increased  levels  of  enzyme  expression.17 S.  boulardii  is  a
east  that  signiﬁcantly  increases  the  activity  of  metabolic
nzymes  in  the  intestinal  mucosa,  stimulates  the  secretion
f  disaccharide  enzymes,  participates  in  the  metabolism  and
bsorption  of  carbohydrates,  and  stimulates  secretory  IgA
roduction  as  the  result  of  a  trophic  effect  on  intestinal
ucosa.18 In  addition,  S.  boulardii  promotes  the  stability
f  the  intestinal  microbiome  and  reduces  the  possibility
f  malabsorption  caused  by  GI  disorders.19 Translocation
f  S.  boulardii  has  not  been  reported;  on  the  contrary,  S.
oulardii  was  reported  to  reduce  bacterial  translocation.20
ased  on  these  properties,  it  was  hypothesized  that  S.
oulardii  could  improve  growth  and  clinical  outcomes  in
reterm  or  low  birth  weight  infants.
Although  several  clinical  trials  strongly  suggest  a  place
or  S.  boulardii  in  the  prevention  and  treatment  of  sev-
ral  GI  diseases  in  adults  and  children,  data  in  preterm
nfants  are  limited.18 S.  boulardii  supplemented  formula
as  shown  to  be  well  tolerated  by  preterm  infants  and  to
ave  beneﬁcial  effects  on  the  GI  microbiome,  bringing  it
loser  to  that  of  breastfed  babies.11 Clinical  trials  in  preterm
nfants  also  suggested  that  S.  boulardii  improved  feeding
olerance  and  reduced  the  risk  of  sepsis.21,22 In  order  to
chieve  optimum  growth  for  a  preterm  infant,  the  goal  is
o  mimic  intrauterine  growth  while  obtaining  a functional
utcome  comparable  to  term  infants.23 A  gain  in  weight
f  15--20  g/kg/day,  in  length  of  0.7--1.0  cm/week,  and  in
ead  circumference  of  0.7  cm/week  is  recommended.24,25
n  the  S.  boulardii  group,  the  average  weight  gain  was
6.14  g/kg/day,  linear  growth  was  0.9  cm/week,  and  head
ircumference  increase  was  0.7  cm/week.  Weight  gain  in
he  control  group  was  10.73  g/kg/day,  which  is  below  the
ecommendation.  The  number  of  days  to  reach  full  enteral
utrition  was  shorter  in  the  S.  boulardii  than  in  the  control
ng  tolerance,  adverse  events  (sepsis,  gastro-intestinal  symp-
d  control  group.
ulardii  Control  p
 ±  1.96  10.73  ±  1.77  g  0.02
4  ±  6.67  112.29  ±  7.24  0.03
±  0.13  1.70  ±  0.45  <0.01
±  0.03  0.72  ±  0.04  0.67
±  0.04  0.87  ±  0.04  0.17
8%)  6  (12.2%)  0.06
 (13.7%)  10/49  (20.4%)  0.05
±  1.6  28.0  ±  1.8  0.035
 vomiting, gastric residuals; S, Saccharomyces.
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roup.  The  better  weight  gain  is  likely  to  be  related  to  the
mprovement  of  feeding  tolerance.  It  was  observed  that  the
ncidence  of  vomiting,  gastric  residual  volume,  and  abdomi-
al  distension  (‘‘GI  symptoms’’,  Table  2)  were  decreased  in
he  intervention  group  in  comparison  to  the  control  group,
lthough  there  was  no  statistical  signiﬁcant  difference.  The
otal  hospital  stay  in  the  S.  boulardii  group  was  shorter  than
hat  in  the  control  group.
No  signiﬁcant  difference  was  observed  in  linear  growth
nd  head  circumference  evolution,  which  could  be  related
o  the  relative  short  intervention  period  of  1  month.  Other
imitations  of  this  study  are  the  lack  of  information  on  post-
atal  clinical  characteristics  of  the  neonates  that  could
ave  been  factors  inﬂuencing  the  outcome,  such  as  the
atio  of  patent  ductus  arteriosus,  intraventricular  hemor-
hage,  and  others.  Information  on  the  number  of  infants
ith  predisposing  factors  for  NEC,  sepsis,  or  other  problems
uch  as  pre-eclampsia,  antenatal  steroid  use,  premature
upture  of  membranes,  and  caesarian  birth  are  missing.
he  absence  of  breastfeeding  is  another  weakness  of  the
tudy.
A  recent  Cochrane  review  reported  on  24  trials  on  pro-
iotics  in  preterm  infants  and  concluded  that  the  trials
ere  highly  variable  with  regard  to  enrollment  crite-
ia  (birth  weight,  gestational  age),  baseline  risk  of  NEC,
iming,  dose,  formulation  of  the  probiotics,  and  feeding
egimens.8 Enteral  supplementation  with  probiotics  signiﬁ-
antly  reduced  the  incidence  of  severe  NEC  (stage  II  or  more)
typical  relative  risk  [RR]  0.43,  95%  conﬁdence  interval  [CI]
.33--0.56;  20  studies,  5529  infants)  and  mortality  (typi-
al  RR  0.65,  95%  CI  0.52--0.81;  17  studies,  5112  infants).8
ccording  to  this  meta-analysis,  there  was  no  evidence  for
 signiﬁcant  reduction  of  nosocomial  sepsis  (typical  RR  0.91,
5%  CI  0.80--1.03;  19  studies,  5338  infants).8 In  the  present
rial,  there  were  no  preterms  who  developed  NEC;  this  is
ikely  to  be  related  to  the  fact  that  gestational  age  for  inclu-
ion  was  30--37  weeks  and  that  NEC  occurs  more  frequently
n  infants  born  with  a  lesser  gestational  age.  Previous  clini-
al  trials  showed  that  S.  boulardii  supplementation  did  not
educe  the  incidence  of  death  or  NEC  in  very  low  birth  weight
nfants,  but  improved  feeding  tolerance  and  reduced  the  risk
f  clinical  sepsis,  while  adverse  effects  related  to  the  intake
f  S.  boulardii  were  not  observed.21,22
S.  boulardii  has  a  protective  effect  against  various
nteric  pathogens  by  two  main  mechanisms:  production
f  factors  that  neutralize  bacterial  toxins  and  modula-
ion  of  the  host  cell  signaling  pathway  implicated  in
roinﬂammatory  response  during  bacterial  infection.18,19 In
ddition,  S.  boulardii  can  increase  the  activity  of  regula-
ory  T  cells  and  secretion  of  IgA  of  intestinal  epithelial
nd  crypt  cells,  improving  intestinal  protection  through
mmune  regulation.18 In  this  study,  there  was  no  statistically
igniﬁcant  difference  in  the  incidence  of  sepsis  between
he  two  groups  (4/51  vs.  6/49).  This  ﬁnding  is  in  agree-
ent  with  the  Cochrane  analysis,  showing  that  the  included
rials  reported  no  systemic  infection  with  the  supplemen-
al  probiotics  organism.8 S.  boulardii  fungemia  has  been
eported  in  patients  with  deep  central  venous  access.18 In
his  clinical  trial,  there  were  no  cases  of  fungemia,  and  no
ide  effects  occurred.  The  authors  of  the  recent  Cochrane
eview  concluded  that  the  updated  review  of  available  evi-
ence  strongly  supports  a  change  in  practice,  meaning  that
1Xu  L  et  al.
robiotics  should  be  given  to  preterm  infants  to  decrease
he  risk  for  NEC  and  mortality.8
In  conclusion,  the  results  of  the  present  study  show  that
rophylactic  use  of  S.  boulardii  in  preterm  infants  acceler-
tes  weight  gain  and  improves  feeding  tolerance.  These  data
onﬁrm  a  recent  retrospective  analysis  concluding  that  pro-
iotics  improve  feeding  tolerance,  leading  to  better  overall
rowth  in  preterm  infants.26 It  is  the  ﬁrst  time  that  better
eight  gain  of  preterm  infants  provided  with  S.  boulardii
as  been  demonstrated.  Future  double-blinded  placebo-
ontrolled  trials  are  needed  to  conﬁrm  these  data.
onﬂicts of  interest
.  Vandenplas  is  a  consultant  for  United  Pharmaceuticals  and
iocodex.  The  others  authors  declare  no  conﬂicts  of  inter-
st.
eferences
1. Collado MC, Cernada M, Neu J, Pérez-Martínez G, Gormaz M,
Vento M. Factors inﬂuencing gastrointestinal tract and micro-
biota immune interaction in preterm infants. Pediatr Res.
2015;77:726--31.
2. Schwiertz A, Gruhl B, Löbnitz M, Michel P, Radke M, Blaut M.
Development of the intestinal bacterial composition in hospital-
ized preterm infants in comparison with breast-fed, full-term
infants. Pediatr Res. 2003;54:393--9.
3. Chauhan M, Henderson G, McGuire W. Enteral feeding for very
low birth weight infants: reducing the risk of necrotising ente-
rocolitis. Arch Dis Child Fetal Neonatal Ed. 2008;93:F162--6.
4. Food and Agriculture Organization of the United Nations (FAO),
World Health Organization (WHO). Guidelines for the evaluation
of probiotics in food. Report of a Joint FAO/WHO Working Group
on drafting guidelines for the evaluation of probiotics in food.
London, Ontario, Canada: FAO, WHO; 2002.
5. Deshpande G, Rao S, Patole S. Probiotics for prevention of
necrotising enterocolitis in preterm neonates with very low
birthweight: a systematic review of randomised controlled tri-
als. Lancet. 2007;369:1614--20.
6. Wang Q, Dong J, Zhu Y. Probiotic supplement reduces risk
of necrotizing enterocolitis and mortality in preterm very
low-birth-weight infants: an updated meta-analysis of 20 ran-
domized, controlled trials. J Pediatr Surg. 2012;47:241--8.
7. Deshpande GC, Rao SC, Keil AD, Patole SK. Evidence-based
guidelines for use of probiotics in preterm neonates. BMC Med.
2011;9:92.
8. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing
enterocolitis in preterm infants. Cochrane Database Syst Rev.
2014;4:CD005496.
9. Vendt N, Grünberg H, Tuure T, Malminiemi O, Wuolijoki E,
Tillmann V, et al. Growth during the ﬁrst 6 months of life
in infants using formula enriched with Lactobacillus rham-
nosus GG:  double-blind, randomized trial. J Hum Nutr Diet.
2006;19:51--8.
0. Senterre T. Practice of enteral nutrition in very low birth weight
and extremely low birth weight infants. World Rev Nutr Diet.
2014;110:201--14.
1. Costalos C, Skouteri V, Gounaris A, Sevastiadou S, Triandaﬁlidou
A, Ekonomidou C, et al. Enteral feeding of premature infants
with Saccharomyces boulardii. Early Hum Dev. 2003;74:89--96.2. Puccio G, Cajozzo C, Meli F, Rochat F, Grathwohl D, Steen-
hout P. Clinical evaluation of a new starter formula for infants
containing live Biﬁdobacterium longum BL999 and prebiotics.
Nutrition. 2007;23:1--8.
22
2
2
2S.  boulardii  in  preterm  infants  
13. Weizman Z, Alsheikh A. Safety and tolerance of a probiotic for-
mula in early infancy comparing two probiotic agents: a pilot
study. J Am Coll Nutr. 2006;25:415--9.
14. Kitajima H, Sumida Y, Tanaka R, Yuki N, Takayama H, Fujimura
M. Early administration of Biﬁdobacterium breve to preterm
infants: randomised controlled trial. Arch Dis Child Fetal Neona-
tal Ed. 1997;76:F101--7.
15. Elmer GW. Probiotics: ‘‘living drugs’’. Am J Health Syst Pharm.
2001;58:1101--9.
16. Talarico TL, Casas IA, Chung TC, Dobrogosz WJ. Production and
isolation of reuterin, a growth inhibitor produced by Lactobacil-
lus reuteri. Antimicrob Agents Chemother. 1988;32:1854--8.
17. Buts JP. Polyamines in milk, in bioactive factors in milk. Ann
Nestle. 1996;54:98--104.
18. Vandenplas Y, Salvatore S, Vieira M, Devreker T, Hauser B. Pro-
biotics in infectious diarrhoea in children: are they indicated?
Eur J Pediatr. 2007;166:1211--8.
19. McFarland LV. Systematic review and meta-analysis of Saccha-
romyces boulardii in adult patients. World J Gastroenterol.
2010;16:2202--22.20. Villar-García J, Hernández JJ, Güerri-Fernández R, González
A, Lerma E, Guelar A, et al. Effect of probiotics (Saccha-
romyces boulardii) on microbial translocation and inﬂam-
mation in HIV-treated patients: a double-blind, randomized,
2301
placebo-controlled trial. J Acquir Immune Deﬁc Syndr. 2015;68:
256--63.
1. Serce O, Benzer D, Gursoy T, Karatekin G, Ovali F. Efﬁcacy of
Saccharomyces boulardii on necrotizing enterocolitis or sepsis
in very low birth weight infants: a randomised controlled trial.
Early Hum Dev. 2013;89:1033--6.
2. Demirel G, Erdeve O, Celik IH, Dilmen U. Saccharomyces
boulardii for prevention of necrotizing enterocolitis in preterm
infants: a randomized, controlled study. Acta Paediatr.
2013;102:e560--5.
3. Agostoni C, Buonocore G, Carnielli VP, De Curtis M, Darmaun
D, Decsi T, et al. Enteral nutrient supply for preterm infants:
commentary from the European Society of Paediatric Gastroen-
terology, Hepatology and Nutrition Committee on Nutrition. J
Pediatr Gastroenterol Nutr. 2010;50:85--91.
4. Georgieff MK. Nutrition. In: MacDonald MG, Seshia MM, Mullet
MD, editors. Avery’s neonatology pathophysiology and manage-
ment of the newborn. 6th ed. Philadelphia: Lippincott Williams
and Wilkins; 2005. p. 380--1.
5. Uhing MR, Das UG. Optimizing growth in the preterm infant.
Clin Perinatol. 2009;36:165--76.
6. Dang S, Shook L, Garlitz K, Hanna M, Desai N. Nutritional out-
comes with implementation of probiotics in preterm infants. J
Perinatol. 2015;35:447--50.
